Orchard Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Orchard Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Sell	79,503 -2,527	-3%	-$35.4K	1.31%	27
2026 Q1	$1.05M	Hold	82,030	–	–	1.1%	29
2025 Q4	$737K	Buy	82,030 +432	+0.5%	+$5.95K	0.64%	29
2025 Q3	$1.41M	Buy	81,598 +2,390	+3%	+$29.4K	1.22%	26
2025 Q2	$743K	Sell	79,208 -106,288	-57%	-$873K	0.82%	29
2025 Q1	$1.32M	Buy	185,496 +173,339	+1,426%	+$1.75M	0.9%	28
2024 Q4	$142K	Buy	12,157 +171	+1%	+$2.67K	0.06%	54
2024 Q3	$246K	Sell	11,986 -158,020	-93%	-$3.64M	0.08%	51
2024 Q2	$3.8M	Sell	170,006 -2,310	-1%	-$55K	1.15%	32
2024 Q1	$4.74M	Buy	172,316 +2,310	+1%	+$64.2K	1.39%	33
2023 Q4	$5.18M	Buy	170,006 +10,851	+7%	+$312K	1.62%	32
2023 Q3	$5.03M	Hold	159,155	–	–	1.86%	31
2023 Q2	$6.49M	Buy	+159,155	New	+$6.45M	2.18%	28

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Orchard Capital Management's NTLA Position: Q2 2026 in Review

Orchard Capital Management reduced its Intellia Therapeutics (NTLA) stake by 3.1% in Q2 2026, selling an estimated $35.4K and leaving 79,503 shares worth $1.35M. The position accounts for 1.31% of the portfolio, ranked #27.

Orchard Capital Management first reported a position in NTLA in Q2 2023 and has held it in 13 quarters since. The position peaked at $6.49M in Q2 2023. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Orchard Capital Management held 79,503 shares of Intellia Therapeutics worth $1.35M as of Q2 2026.
Orchard Capital Management sold 2,527 Intellia Therapeutics shares in Q2 2026, an estimated $35.4K.
Intellia Therapeutics made up 1.31% of Orchard Capital Management's portfolio in Q2 2026, its #27 holding.
Orchard Capital Management first reported a position in Intellia Therapeutics in Q2 2023 and has held it in 13 quarters since.
Orchard Capital Management's Intellia Therapeutics position peaked at $6.49M in Q2 2023.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Orchard Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.